Biotech Values

[DewDiligence]

Demosumab Phase-3 Scorecard

The phase-3 denosumab program is one of the largest ever
conducted for any drug by any company. All told, there are
22 phase-3 trials spanning numerous indications (although
some of them are open-label extension trials to assess long-term
safety that are effectively phase-4’s). The following table includes
the most consequential phase-3 trials; they fall into three main
groups: metastatic cancer, non-metastatic cancer, and post-
menopausal osteoporosis.

 
                            Primary   No. of  Completion 
 Indication         Comprtr Endpoint Patients   Date*    Outcome  Link 
 Met BCa            Zometa   TTFSE     2,049   compltd   superior http://clinicaltrials.gov/ct2/show/NCT00321464 
 Misc met cancer    Zometa   TTFSE     1,779   compltd   non-infr http://clinicaltrials.gov/ct2/show/NCT00330759 
 HRPC               Zometa   TTFSE     1,904     3/10      n/a    http://clinicaltrials.gov/ct2/show/NCT00321620 
 HRPC               placebo  PFS       1,435     5/10      n/a    http://clinicaltrials.gov/ct2/show/NCT00286091 
  
 Non-met BCa        placebo† TTFF      2,800     3/12      n/a    http://clinicaltrials.gov/ct2/show/NCT00556374 
 Non-met PCa        placebo‡ BMD       1,468   compltd   success  http://clinicaltrials.gov/ct2/show/NCT00089674 
 nmBCa/osteopenia   placebo  bone loss   252   compltd   success  http://clinicaltrials.gov/ct2/show/NCT00089661 
  
 1-line osteoprsis  placebo  fractures 7,200   compltd   success  http://clinicaltrials.gov/ct2/show/NCT00089791 
 1-line osteoprsis  Fosamax  BMD       1,189   compltd   success  http://clinicaltrials.gov/ct2/show/NCT00330460 
 2-line osteoprsis  Boniva   BMD         800     3/11      n/a    http://clinicaltrials.gov/ct2/show/NCT00936897 
 Osteopenia         placebo  BMD         332   compltd   success  http://clinicaltrials.gov/ct2/show/NCT00091793 
 Fosamax switch     Actonel  BMD         800     9/11      n/a    http://clinicaltrials.gov/ct2/show/NCT00919711 
 Fosamax switch     placebo  BMD         504   compltd   success  http://clinicaltrials.gov/ct2/show/NCT00377819 
  
 *For analysis of primary endpoint. 
 †All patients receive an aromatase inhibitor. 
 ‡All patients receive androgen-deprivation therapy.